Researchers at the University of Rochester tested whether a simple home exercise plan and low-dose ibuprofen can ease “Chemo brain” symptoms in people undergoing chemotherapy, and the phase 2 results show exercise had the clearest benefit while ibuprofen produced smaller, less consistent gains; larger trials are planned to confirm these early findings and to refine dosing and duration.
“Chemo brain” (also called chemotherapy-related cognitive impairment, or CRCI) can sap memory, focus and multitasking at precisely the time patients need mental stamina most. Prior work has suggested as many as 80% of people who receive chemotherapy experience some level of cognitive trouble, making practical, low-risk options worth exploring. This trial tried a pragmatic, patient-friendly approach instead of complex new drugs.
The phase 2 study enrolled 86 adults getting chemotherapy in New York, with an average age of 53 and nearly 89% of participants identifying as women. Participants were experiencing cognitive symptoms and were randomly assigned to different interventions to see what might move the needle. That mix reflects the real-world variety of patients who report these issues.
Patients went into one of four groups: a home exercise program tailored for cancer patients; the same exercise plus ibuprofen at 200 milligrams twice daily; ibuprofen alone; or a placebo pill alone. The ibuprofen dose used is lower than many over-the-counter regimens but was intended to test a modest anti-inflammatory effect. Random assignment allowed researchers to compare physical activity, anti-inflammatory treatment, and their combination.
The exercise routine emphasized low to moderate intensity activity that patients could do at home, including progressive walking and resistance-band strength work. It was designed to be manageable during chemotherapy, not one more burden. The goal was steady, achievable movement rather than intense training.
“This is one of the first studies specifically designed to assess these interventions for cancer-related cognitive impairment during chemotherapy in patients with multiple diseases using both performance-based cognitive assessments and patient-reported outcomes,” said lead author Michelle C. Janelsins, Ph.D., MPH, of the University of Rochester and the Wilmot Cancer Institute, in the press release.
After six weeks the clearest signal came from exercise: participants in the exercise groups showed improved attention and cognitive function compared with placebo. Those who combined exercise with placebo pills fared better on attention measures than the plain placebo group, suggesting the activity itself was the key driver. The pattern pointed to cognitive gains that are meaningful for daily life.
Participants who took only ibuprofen also showed cognitive improvements relative to placebo, but those gains were generally smaller and less consistent than the benefits tied to exercise. That suggests inflammation might play a role in chemotherapy-related cognitive symptoms, and that anti-inflammatory medications could be part of a therapeutic strategy. Still, ibuprofen was not a slam-dunk replacement for moving the body.
“We are encouraged by the findings of this trial that suggest possible benefits of both interventions for some cognitive domains,” Janelsins said. “Clearly, we saw a more pronounced effect with exercise, which is notable considering the multiple health benefits of exercise for cancer survivors.” No adverse side effects were reported during the trial, which adds practical appeal to the approach.
The researchers acknowledged limits, including the small sample size, short follow-up and the fact that most participants were women, which may limit how broadly the results apply. Some cognitive measures did not change, so benefits were domain specific rather than universal. Those caveats are exactly why the team is moving toward larger studies.
Investigators are planning phase 3 trials to test whether the combination of exercise and anti-inflammatory treatment holds up in bigger, longer studies. “Since we saw cognitive benefits in some domains and not others, we will also consider additional doses and longer durations in future research trials,” said Janelsins. Patients are urged to talk with their oncology team before starting ibuprofen or new exercise plans, because interactions with treatment or medical conditions can change risks and benefits.
